Skip to Content
Merck
CN

Key Documents

View All Documentation

EHU052971

MISSION® esiRNA

targeting human TRIM37

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CATCTTAGCCCCCAAAATGATGATGCTCTGGAGACACGAGCTAAGAAGTCTGCATGCTCTGACATGCTTCTCGAAGGTGGTCCTACTACAGCTTCTGTAAGAGAGGCCAAAGAGGATGAAGAAGATGAGGAGAAGATTCAGAATGAAGATTATCATCACGAGCTTTCAGATGGAGATCTGGATCTGGATCTTGTTTATGAGGATGAAGTAAATCAGCTCGATGGCAGCAGTTCCTCTGCTAGTTCCACAGCAACAAGTAATACAGAAGAAAATGATATTGATGAAGAAACTATGTCTGGAGAAAATGATGTGGAATATAACAACATGGAATTAGAAGAGGGAGAACTCATGGAAGATGCAGCTGCTGCAGGACCCGCAGGTAGTAGCCATGGTTATGTGGGTTCCAGTAGTAGAATATCAAGAAGAACACATTTATGCTCCGCTGCTACC

Ensembl | human accession no.

ENSG00000108395

NCBI accession no.

NM_015294

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... TRIM37(4591)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
KXU
OWU

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Guosheng Tan et al.
International journal of clinical oncology, 26(3), 532-542 (2021-01-03)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in the worldwide. Sorafenib is approved for first-line therapy against advanced HCC, but chemo-resistance is still a leading cause of tumor relapse and treatment failure in HCC. Thus, there is
Fernando R Balestra et al.
eLife, 10 (2021-01-26)
TRIM37 is an E3 ubiquitin ligase mutated in Mulibrey nanism, a disease with impaired organ growth and increased tumor formation. TRIM37 depletion from tissue culture cells results in supernumerary foci bearing the centriolar protein Centrin. Here, we characterize these centriolar

Global Trade Item Number

SKUGTIN
EHU052971-50UG04061828338245
EHU052971-20UG04061828573790